Q2 2023 EPS Estimates for Edwards Lifesciences Co. Lowered by SVB Leerink (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EWGet Rating) – Equities researchers at SVB Leerink reduced their Q2 2023 EPS estimates for shares of Edwards Lifesciences in a research note issued on Tuesday, April 26th. SVB Leerink analyst D. Antalffy now forecasts that the medical research company will post earnings of $0.68 per share for the quarter, down from their previous forecast of $0.74. SVB Leerink has a “Outperform” rating and a $132.00 price objective on the stock.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.03. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. Edwards Lifesciences had a return on equity of 26.53% and a net margin of 28.73%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.54 EPS.

Several other equities analysts have also recently issued reports on the company. Wolfe Research assumed coverage on Edwards Lifesciences in a research report on Tuesday, April 5th. They issued an “outperform” rating and a $134.00 price target on the stock. Piper Sandler dropped their price target on Edwards Lifesciences from $133.00 to $125.00 in a research report on Thursday, January 27th. Credit Suisse Group boosted their target price on Edwards Lifesciences from $131.00 to $144.00 and gave the stock an “outperform” rating in a research report on Friday, January 7th. Stifel Nicolaus dropped their target price on Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday, January 27th. Finally, Raymond James dropped their target price on Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating on the stock in a research report on Thursday, January 27th. Three analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Buy” and a consensus target price of $128.87.

Shares of EW stock opened at $109.77 on Friday. The stock has a market capitalization of $68.20 billion, a PE ratio of 45.93, a price-to-earnings-growth ratio of 3.52 and a beta of 1.15. Edwards Lifesciences has a 52-week low of $87.32 and a 52-week high of $131.73. The stock’s 50-day moving average price is $114.12 and its 200 day moving average price is $115.57. The company has a quick ratio of 2.38, a current ratio of 3.08 and a debt-to-equity ratio of 0.10.

Several large investors have recently bought and sold shares of the company. CX Institutional raised its holdings in Edwards Lifesciences by 7.7% during the third quarter. CX Institutional now owns 1,243 shares of the medical research company’s stock worth $141,000 after buying an additional 89 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Edwards Lifesciences by 14.6% during the first quarter. Lindbrook Capital LLC now owns 738 shares of the medical research company’s stock worth $87,000 after buying an additional 94 shares during the last quarter. Midwest Professional Planners LTD. raised its holdings in Edwards Lifesciences by 0.5% during the fourth quarter. Midwest Professional Planners LTD. now owns 21,563 shares of the medical research company’s stock worth $2,793,000 after buying an additional 105 shares during the last quarter. McIlrath & Eck LLC raised its holdings in Edwards Lifesciences by 7.2% during the fourth quarter. McIlrath & Eck LLC now owns 1,584 shares of the medical research company’s stock worth $205,000 after buying an additional 106 shares during the last quarter. Finally, Pinnacle Bancorp Inc. raised its holdings in Edwards Lifesciences by 18.6% during the first quarter. Pinnacle Bancorp Inc. now owns 701 shares of the medical research company’s stock worth $83,000 after buying an additional 110 shares during the last quarter. 81.91% of the stock is currently owned by institutional investors.

In related news, VP Larry L. Wood sold 4,386 shares of the company’s stock in a transaction that occurred on Tuesday, February 8th. The shares were sold at an average price of $109.55, for a total transaction of $480,486.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kieran Gallahue sold 32,256 shares of the company’s stock in a transaction that occurred on Tuesday, February 8th. The stock was sold at an average price of $110.79, for a total transaction of $3,573,642.24. The disclosure for this sale can be found here. Insiders have sold a total of 234,531 shares of company stock valued at $26,097,538 in the last ninety days. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.